Healthcare Co Ltd (603313) fair value: what the stock is really worth
As of Oct 8, 2026: fair value of Healthcare Co Ltd ¥11.70, price ¥6.22, upside +88.1%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ¥5.05 – ¥24.80 · fair‑value band ¥8.34 – ¥15.05 · the ¥6.22 price screens below the ¥11.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Healthcare Co in your weekly email
Every Wednesday you see whether Healthcare Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Healthcare Co.,Ltd. provides memory foam mattresses and other home products in China. The company offers smart mattresses and sofas, anti-snoring pillows, and electric beds. It sells its products under the MLILY brand name. The company was formerly known as Nantong Hengkang Sponge Products Co., Ltd. Healthcare Co., Ltd.
Show more
Healthcare Co.,Ltd. provides memory foam mattresses and other home products in China. The company offers smart mattresses and sofas, anti-snoring pillows, and electric beds. It sells its products under the MLILY brand name. The company was formerly known as Nantong Hengkang Sponge Products Co., Ltd. Healthcare Co., Ltd. was founded in 2003 and is based in Rugao, China.
Stock analysis
Healthcare Co Ltd (603313) currently trades at ¥6.22, while our model-based Fair Value estimate is ¥11.70, implying the stock looks roughly 46.8% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥19.12 per share, and 13 of the 16 models we run sit above the ¥6.22 price.
Bear case: the Dividend Discount group reads lowest at ¥2.46, and 3 of the 16 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥8.34 (bear) to ¥15.05 (bull), the price of ¥6.22 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Consumer Cyclical sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Healthcare Co Ltd reported revenue of 8.9B CNY in FY2025 versus 8.1B CNY in FY2021, a compound +2.3%/yr. Reported net income was −9.8M CNY in FY2025.
Key figures
Market cap 3.5B CNY (≈ $530M) · P/S ratio 0.38 · EPS (TTM) ¥−0.2100 · Dividend yield 3.1% · Net margin −0.1% · Return on equity −3.4% · Return on assets (EBIT) 0.4% · Operating margin 4.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at 29% fair-value upside, at 88%, 603313 screens cheaper than that median.
Fair Value models
Bear ¥8.34Fair Value ¥11.70Bull ¥15.05
Price ¥6.22 · Upside +88.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+5.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Start year 2020 (pandemic). Over 10 years: +20.5% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.9% (2020) → 4.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.8%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −4.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Furnishings, Fixtures & Appliances · 307 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Healthcare Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/603313
Frequently asked questions
Is Healthcare Co Ltd (603313) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ¥11.70 versus a price of ¥6.22, about +88% upside (undervalued).
What is the fair value of 603313?
Our model-based fair value for Healthcare Co Ltd is ¥11.70 (as of Oct 1, 2026), built from audited fundamentals. The current price: ¥6.22.
What is the quality score of 603313?
Healthcare Co Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Healthcare Co Ltd (603313)?
Our model-based price target is the fair value of ¥11.70 (as of Oct 1, 2026) from 16 valuation models. Cautious scenario ¥8.34, optimistic scenario ¥15.05. It is a calculation from audited fundamentals, not an analyst target.
What is the Healthcare Co Ltd stock forecast for 2026?
Our models put fair value at ¥11.70, about +88% upside versus a price of ¥6.22 (undervalued). Cautious scenario ¥8.34, optimistic scenario ¥15.05. The calculation is refreshed regularly with new filings.
What is the revenue of Healthcare Co Ltd (603313)?
Healthcare Co Ltd reported trailing-twelve-month revenue of about 9.3B CNY (latest available figure, as of Oct 1, 2026).
Does Healthcare Co Ltd pay a dividend?
Healthcare Co Ltd currently shows a dividend yield of about 3.10% relative to its recent price (as of Oct 1, 2026).
What growth is priced into Healthcare Co Ltd (603313)?
For today's price to be fair in a discounted-cash-flow model, Healthcare Co Ltd would have to grow free cash flow by -2.8 % per year for five years (discount rate 10.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.4 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of 603313 use?
Our models discount Healthcare Co Ltd at 10.7 %: a base by market capitalisation (small), damped by beta 0.58, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Healthcare Co Ltd that is -2.8 % per year a year over ten years, using the same discount rate (10.7 %) and the same formula as our fair value.
How much growth has Healthcare Co Ltd (603313) delivered so far?
Over the past 5 years revenue at Healthcare Co Ltd grew +6.4 % a year. The price currently implies -2.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Healthcare Co Ltd (603313) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Healthcare Co Ltd (-2.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Healthcare Co Ltd (603313)?
The free-cash-flow yield on the price is 14.00 %: that much free cash flow Healthcare Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Healthcare Co Ltd (603313)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Healthcare Co Ltd it is ¥11.70 per share (as of Oct 1, 2026), against a price of ¥6.22. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Healthcare Co Ltd stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 603313 trades below its calculated fair value: price ¥6.22, fair value ¥11.70, a gap of about +88% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603313?
No. The price is what the market pays today (¥6.22); the fair value is what the company's own numbers justify (¥11.70). For Healthcare Co Ltd the two are ¥5.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Healthcare Co Ltd worth?
The market values Healthcare Co Ltd at about 3.5B CNY (market capitalisation, as of Oct 1, 2026). Per share that is ¥6.22; our models calculate a fair value of ¥11.70 per share.
What do the bullish and bearish scenarios say about 603313?
Our models span a range for Healthcare Co Ltd: cautious scenario ¥8.34, base ¥11.70, optimistic ¥15.05 per share (as of Oct 1, 2026, price ¥6.22). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Healthcare Co Ltd (603313)?
Balance-sheet figures for Healthcare Co Ltd (as of Oct 1, 2026): return on equity −3.4%, debt of 0.07 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 603313 from its 52-week high?
Healthcare Co Ltd trades at ¥6.22, about 41% below its 52-week high of ¥10.58 and 23% above the low of ¥5.05 (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of ¥11.70 is for.
Which stocks are comparable to Healthcare Co Ltd?
From the same area (Consumer Cyclical) we also value Midea Group, King Slide Works Co, Gree Electric Appliances, Inc, Haier Smart Home Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Healthcare Co Ltd stock attractive at the current price?
The data as of Oct 1, 2026: price ¥6.22, calculated fair value ¥11.70 (+88%), Quality Score 45/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603313 calculated?
We run Healthcare Co Ltd through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥11.70, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Healthcare Co Ltd currently trades 47 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Healthcare Co Ltd (603313)?
The closing price on Oct 8, 2026 was ¥6.22. Our model-based fair value is ¥11.70, about +88% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Healthcare Co Ltd right now?
The price is below even our cautious bear case (¥8.34). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (45/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (¥8.34 to ¥15.05) leaves room in how you read the outcome.
Where does the earnings growth of Healthcare Co Ltd (603313) come from?
Earnings per share at Healthcare Co Ltd grew −11.5 % a year from 2013 to 2024. Broken into its drivers: revenue per share +19.1 %, EBIT margin −21.9 %, tax rate −2.8 %, residual (interest, one-offs) −2.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Healthcare Co Ltd
How large is the market capitalisation of Healthcare Co Ltd (603313)?
The market capitalisation of Healthcare Co Ltd is 3.5B CNY (≈ $530M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Healthcare Co Ltd (603313)?
The price-to-sales ratio of Healthcare Co Ltd is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Healthcare Co Ltd (603313)?
Earnings per share at Healthcare Co Ltd are ¥−0.2100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Healthcare Co Ltd (603313)?
The dividend yield of Healthcare Co Ltd is 3.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Healthcare Co Ltd (603313)?
The net margin of Healthcare Co Ltd is −0.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Healthcare Co Ltd (603313)?
The return on equity (ROE) of Healthcare Co Ltd is −3.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Healthcare Co Ltd (603313)?
On an EBIT basis the return on assets of Healthcare Co Ltd is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Healthcare Co Ltd (603313)?
The operating margin of Healthcare Co Ltd is 4.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Healthcare Co Ltd (603313)?
Revenue at Healthcare Co Ltd is growing +5.8% versus a year earlier (3y avg +3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Healthcare Co Ltd (603313)?
Earnings per share at Healthcare Co Ltd are growing −15.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Healthcare Co Ltd (603313) carry?
The net debt of Healthcare Co Ltd is 983M CNY (fiscal year 2025, ≈ 2.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Healthcare Co Ltd in the live analysis
One click puts Healthcare Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
